Abstract
The prepared film-coated directly-compressed indomethacin, indomethacin sodium and indomethacin meglumine tablets, plain indomethacin in hard gelatin capsule and the commercial product ''Indocid''capsules, were subjected to bioavailability testing in six healthy volunteers. Each treatment was given as single oral dose of 50 mg. The excreted drug was estimated in urine at 1, 2, 4, 6, 8, 10, 12 and 24 hours post-drug administration. The cumulative amount excreted, percent dose excreted, (Q)(max), (t)(max), (K)(el), (t)(1/2el) and relative bioavailability, to plain drug, were determined. The obtained results revealed that directly-compressed film-coated indomethacin meglumine tablets had the best relative bioavailability than the other treatments.